{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031356","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.431437+00:00","generated_at":"2026-06-21T22:08:03.578814+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elite Pharmaceuticals and Lannett terminate Vigabatrin agreement; marketing rights return to Elite","bullets":["Joint termination of License, Supply and Distribution Agreement for Vigabatrin effective Nov 9, 2022.","All marketing rights for Vigabatrin revert to Elite Pharmaceuticals.","Agreement was with Lannett Company, Inc.; no further details on reason or financial impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031356","json":"https://secwatch.observer/filing/0001493152-22-031356.json","markdown":"https://secwatch.observer/filing/0001493152-22-031356.md","text":"https://secwatch.observer/filing/0001493152-22-031356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/0001493152-22-031356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:08:03.578814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f88450101b2b979b5aaa4e9800254cab42ae167","claim":"ELITE PHARMACEUTICALS INC /NV/ terminated License, Supply and Distribution Agreement with Lannett Company, Inc. (effective 2022-11-09).","evidence_excerpt":"On November 9, 2022, Elite Pharmaceuticals Inc. (“Elite”) and Lannett Company, Inc. (“Lannett”) jointly terminated the License, Supply and Distribution Agreement for Vigabatrin effective as of November 9, 2022.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/0001493152-22-031356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Lannett Company, Inc."},{"label":"Effective","value":"2022-11-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}